Dr. Fakhri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Palo Alto, CA 94304Phone+1 650-723-4000
Summary
- Dr. Bita Fakhri is an oncologist in San Francisco, CA and is affiliated with UCSF Medical Center. She received her medical degree from Iran University of Medical Sciences and has been in practice 8 years. She also speaks multiple languages, including Farsi. She specializes in hematologic oncology.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2015 - 2018
Boston University Medical CenterResidency, Internal Medicine, 2012 - 2015
Yale School of Public HealthMPH, Epidemiology, 2010 - 2011
Iran University of Medical SciencesClass of 2009
Certifications & Licensure
CA State Medical License 2017 - 2025
MO State Medical License 2016 - 2019
MA State Medical License 2012 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Start of enrollment: 2018 Nov 16
- Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation Start of enrollment: 2019 May 07
- The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2020 Dec 03
Publications & Presentations
PubMed
- Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, Nicole Lamanna, Beenish S Manzoor
American Journal of Hematology. 2024-12-19 - Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach
Haematologica. 2024-10-03 - Pericardial events associated with ibrutinib-based therapies for chronic lymphocytic leukaemia in two landmark trials.Bita Fakhri, Victoria Wang, Gabriela Perez-Burbano, Anna Wall, Sumithra Mandrekar
British Journal of Haematology. 2024-10-01
Abstracts/Posters
- Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular TherapiesBita Fakhri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin LymphomaBita Fakhri, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Dr. Fakhri on Ongoing Clinical Trials in CLLFebruary 17th, 2020- Dr. Fakhri on the Use of PI3K Inhibitors in Relapsed/Refractory CLLJanuary 24th, 2020
- Advances Continue at Rapid Pace in CLL ParadigmJanuary 21st, 2020
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Other Languages
- Farsi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
